We hypothesized that baseline characteristics including sex; age; obesity classification (class 1 vs. classes 2 and 3); presence of abnormal liver transaminases [aspartate aminotransferase (AST), alanine aminotransferase (ALT)]; elevated hemoglobin A1c; depression, anxiety, hunger, and binge eating tendencies; and additional eating-related behaviors would be associated with topiramate plus lifestyle modification response 1.5, 3, 6, and 12 months after initiation. The gene discussed is GPT; the disease is depressive disorder.